Johnson & Johnson MedTech Archives - Page 6 of 7

J&J’s Ethicon completes first robot-assisted kidney stone removal with Monarch platform

The Monarch platform for robot-assisted urology procedures. [Image courtesy of Johnson & Johnson’s Ethicon]Ethicon, a Johnson & Johnson MedTech company, today announced the first robotic-assisted removal of kidney stones using the Monarch platform.

Auris Health, an Ethicon subsidiary, received FDA clearance for Monarch for endourological procedures in May 2022. The University of California, Irvine’s UCI Health used the Monarch platform for urology to complete the first procedure.

According to a news release, it’s the first successful robotically assisted, electromagnetic-guided percutaneous access and mini-percutaneous nephrolithotomy procedure. Ethicon said its study involves a collaboration with co-investigator Dr. Mihir Desai from the University of Southern California.

“This clinical study is the first in the world to research and demonstrate the potential for improved navigation, access, clearance and control in mini-PCNL proce…

DeviceTalkers assemble for the final Newsmakers of 2022

In this episode, your diligent team of DeviceTalkers assembled to review our Top 10 events, trends and newsmakers of 2022.

Executive Editor Chris Newmarker, Pharma Editor Brian Buntz, Managing Editor Jim Hammerand, Senior Editor Danielle Kirsh and Associate Editor Sean Whooley joined me, DeviceTalks Editorial Director Tom Salemi, for the latest DeviceTalks podcast.

We’ve got some highs — robots, diabetes — and some lows — supply chain, recalls — and a whole lot of interesting things in between. All-in-all, we’re bullish on what’s to come in 2023! And we only mentioned COVID-19 once.

Companies mentioned in our wide-ranging discussion include Abbott, Abiomed, Ambu, Becton Dickinson, Boston Scientific, CMR Surgical, Dexcom, embecta, Intuitive, Johnson & Johnson Medtech, Medtronic, Neuralink, Philips, Senseonics, Stryker, Synchron, Vicarious Surgical, Zimmer Biomet, ZimVie and many more.

You can listen to other DeviceTalks Podcast Network shows at…

The top 10 cardiac device stories of 2022

[Image from Pixabay]From pulsed-field ablation to non-invasive monitoring, this was an exciting year for cardiac device tech.

Here are the top 10 cardiac device stories from MassDevice and its sister sites:

10. Medtronic to pay Acutus $17M following EU MDR submission of left-heart access portfolio

Earlier this year, Acutus agreed to sell its left-heart access portfolio to Medtronic for $50 million.

9. Abbott confirms first implants of its dual-chamber leadless pacemaker system

The company designed its i2i technology to provide beat-by-beat communication between two leadless pacemakers, with one positioned on the right ventricle and the other in the right atrium.

8. Boston Scientific completes $1.75B Baylis Medical acquisition

The deal expanded Boston Scientific’s electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG and VersaCross transseptal platforms. It also gained a family of guidewires, sheaths an…

Johnson & Johnson completes $16.6B Abiomed acquisition

Johnson & Johnson (NYSE:JNJ) announced today that it completed its $16.6 billion acquisition of Abiomed (Nasdaq:ABMD).

Abiomed now becomes part of Johnson & Johnson, operating as a standalone business within its MedTech segment.

“We are excited to officially welcome the talented Abiomed team to Johnson & Johnson. Their patient-first philosophy aligns with our credo and our purpose to change the future of health for humanity,” said Joaquin Duato, CEO of Johnson & Johnson. “This acquisition marks another important step on Johnson & Johnson’s path to accelerating growth in our MedTech business and delivering innovative medical technologies to more people around the world.”

Last month, Johnson & Johnson announced its intention to acquire Abiomed for approximately $16.6 billion. Under the agreement, Johnson & Johnson intends to acquire through tender offer all outstanding Abiomed shares.

Johnson & Johnson last week exten…

Johnson & Johnson extends tender offer for Abiomed acquisition

Johnson & Johnson (NYSE:JNJ) announced today that it extended the expiration date of its offer to acquire Abiomed (Nasdaq:ABMD).

Last month, Johnson & Johnson announced its intention to acquire Abiomed for approximately $16.6 billion. Under the agreement, Johnson & Johnson intends to acquire through tender offer all outstanding Abiomed shares.

The deal includes an upfront payment of $380 per share in cash. Abiomed shareholders also receive a non-tradeable contingent value right (CVR). This entitles the holder to receive up to $35 per share in cash upon the achievement of certain commercial and clinical milestones. Both companies boards of directors approved the transaction.

Upon announcing the transaction, Johnson & Johson said it intends to complete it before the end of the first quarter of 2023.

About the extension

Johnson & Johnson’s offer was previously scheduled to expire at 11:59 p.m. ET on Dec. 13, 2022, according …

CMR Surgical and J&J are partnering on surgical robotics

Versius surgical robotics systems [Image courtesy of CMR Surgical]CMR Surgical announced today that Johnson & Johnson MedTech’s Ethicon business will work with CMR to sell its Versius surgical robotics systems in select markets.

The collaboration involves commercial teams from the two companies working together. They’ll focus on selling to select hospitals in Italy, France, Germany and Brazil.

“By entering into this collaboration agreement with Ethicon in select markets, CMR believes that this combination of expertise in minimal access surgery and digital innovation will deliver an optimized offering to customers” CMR Surgical CEO Per Vegard Nerseth said in a news release. “CMR looks forward to progressing this agreement in strategically important regions as CMR continues to rapidly expand on a global scale.”

The news comes only weeks after the Cambridge, U.K.–based surgical robotics upstart announced that it had inst…

New results detail J&J Embotrap design’s first-pass performance in stroke patients

A blood clot captured by the Embotrap stent retriever [Photo courtesy of Johnson & Johnson MedTech]

Johnson & Johnson (NYSE:JNJ) has released results for its Embotrap stent retrievers showing the next-generation design’s success in removing blood clots from ischemic stroke patients.

Johnson & Johnson MedTech’s Cerenovus subsidiary tracked outcomes for 1,000 ischemic stroke patients who underwent mechanical thrombectomy procedures with Embotrap devices as a first-line therapy.

“The positive preliminary findings of this research provide real-world results that demonstrate advances are possible in mechanical thrombectomy procedures to treat ischemic stroke,” Cerenovus Worldwide President Mark Dickinson said in a news release. “It is encouraging to see these positive results and realize the impact this data can have on improved patient outcomes and changing the trajectory of stroke.”<…

J&J MedTech names new innovation and R&D head

Ahmet Tezel will serve as Johnson & Johnson MedTech’s global head of medtech innovation and R&D. [Photo courtesy of J&J MedTech]

Johnson & Johnson MedTech today announced the promotion of Ahmet Tezel, Ph.D., to the position of Company Group Chairman and Global Head of MedTech Innovation and R&D.

Tezel will replace Peter Shen, Ph.D., who will retire from the role at the end of this year after a J&J career spanning more than 25 years.

Tezel will join the Medtech global leadership team and report to J&J MedTech EVP and Worldwide Chair Ashley McEvoy as the unit focuses on making its products and services “smarter, less invasive, and more personalized,” the company said in a news release.

RELATED: Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders

Tezel currently serves as worldwide VP of R&D for J&J Me…

Abiomed stock skyrockets on Q3 results ahead of Johnson & Johnson acquisition

Abiomed (Nasdaq:ABMD) shares soared before hours on third-quarter results and the news of its acquisition by Johnson & Johnson (NYSE:JNJ).

Johnson & Johnson announced this morning that it agreed to buy Abiomed for $16.6 billion.

Shares of ABMD skyrocketed up more than 50% at $378.30 apiece in morning trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 2%.

The Danvers, Massachusetts-based company posted profits of $106.1 million for the quarter. That totals $2.32 per share on sales of $265.9 million for the three months ended Sept. 30, 2022.

Abiomed reported an 86.4% bottom-line gain on year-over-year sales growth of 7.2%.

The company said it saw impacts on procedural volumes in July due to extended physician vacations. That, paired with ongoing hospital labor shortages, affected sales. Additionally, Abiomed observed improvements in patient utilization…

Johnson & Johnson to acquire Abiomed for $16.6B

Johnson & Johnson (NYSE:JNJ) announced today that it agreed to acquire Abiomed (Nasdaq:ABMD) for approximately $16.6 billion.

Under the agreement, Johnson & Johnson intends to acquire through tender offer all outstanding Abiomed shares. That amounts to an upfront payment of $380 per share in cash. Johnson & Johson plans to complete the transaction before the end of the first quarter of 2023.

Shares of ABMD skyrocketed up more than 50% at $378.30 apiece in morning trading today. The company also reported its third-quarter earnings this morning. Meanwhile, JNJ shares dipped slightly at $172.82 apiece. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 2%.

Abiomed shareholders will receive a non-tradeable contingent value right (CVR). This entitles the holder to receive up to $35 per share in cash upon the achievement of certain commercial and clinical milestones. B…

5 top trends shaping the medtech industry

Ashley McEvoy (left), Michael Minogue (middle) and Barry Rosenberg (right) speak at AdvaMed’s The MedTech Conference in Boston.

Ashley McEvoy is an industry veteran and the EVP and worldwide chair of Johnson & Johnson MedTech. Michael Minogue, another veteran, serves as chair, president and CEO of heart pump maker Abiomed.

Together, the two bring a wealth of medtech industry knowledge to the table. They demonstrated that in a “CEOs Unplugged” discussion at AdvaMed’s The MedTech Conference today.

McEvoy and Minogue joined Boston Consulting Group Managing Director and Senior Partner Barry Rosenberg onstage to discuss major medtech trends. The two went in-depth on five that they see in the industry right now: AI, health equity, hospital care, talent and climate change.

Here is more about the five trends:

1. AI

McEvoy said there is discussion over the potential framework for how to embrace artificial intelligence (AI) and m…

How Johnson & Johnson is looking to lead the way in ablation

“If you want to go fast, go alone. If you want to go forward, go together,” Johnson & Johnson’s Celine Martin (left) said of innovation during a DeviceTalks West 2022 keynote interview with MassDevice executive editor Chris Newmarker (right). [Image by Kara Singleton, WTWH Media]Celine Martin, Johnson & Johnson group chair, cardiovascular & specialty solutions (CSS) group, oversees high-growth areas at the company’s global MedTech business.

Her leadership covers Acclarent, Biosense Webster, Cerenovus and Mentor. Together, those companies bring in more than $5 billion in annual sales with more than 14,000 employees.

Over 25 years at Johnson & Johnson, Martin has looked to improve standards of care for AFib, stroke and minimally invasive surgery. At DeviceTalks West in Santa Clara last week, she spoke in a keynote address about how she’s done it.

On treating AFib at Biosense Webster

Martin said at DeviceTalks that…